{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:39:04Z","timestamp":1762144744745},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/spc.0b013e32833d3024","type":"journal-article","created":{"date-parts":[[2010,7,28]],"date-time":"2010-07-28T06:57:26Z","timestamp":1280300246000},"page":"189-194","source":"Crossref","is-referenced-by-count":8,"title":["Medical management of metastatic bone disease"],"prefix":"10.1097","volume":"4","author":[{"given":"Naveen S","family":"Vasudev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet E","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20211004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3111\/200710027039","article-title":"Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia","volume":"10","author":"Sureda","year":"2007","journal-title":"J Med Econ"},{"key":"R2-14-20211004","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.ejca.2008.11.013","article-title":"The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22","volume":"45","author":"Chow","year":"2009","journal-title":"Eur J Cancer"},{"key":"R3-14-20211004","doi-asserted-by":"crossref","first-page":"6209s","DOI":"10.1158\/1078-0432.CCR-06-1213","article-title":"Advances in treating metastatic bone cancer: summary statement for the first Cambridge conference","volume":"12","author":"Lipton","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R5-14-20211004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0304-3959(98)00138-9","article-title":"Assessment and treatment of neuropathic cancer pain following WHO guidelines","volume":"79","author":"Grond","year":"1999","journal-title":"Pain"},{"key":"R6-14-20211004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/SPC.0b013e328336289c","article-title":"Under-treatment of cancer pain","volume":"4","author":"Fairchild","year":"2010","journal-title":"Curr Opin Support Palliat Care"},{"key":"R7-14-20211004","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/sj.bjc.6605053","article-title":"Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group","volume":"100","author":"Apolone","year":"2009","journal-title":"Br J Cancer"},{"key":"R9-14-20211004","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.ejca.2009.01.007","article-title":"A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal","volume":"45","author":"Oldenmenger","year":"2009","journal-title":"Eur J Cancer"},{"key":"R10-14-20211004","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1006\/bbrc.1996.1113","article-title":"Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes","volume":"224","author":"Rogers","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"R11-14-20211004","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0885-3924(97)00075-4","article-title":"A randomized controlled trial of intravenous clodronate in patients with metastatic bone disease and pain","volume":"13","author":"Ernst","year":"1997","journal-title":"J Pain Symptom Management"},{"key":"R12-14-20211004","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/bjc.1994.344","article-title":"High dose intravenous pamidronate for metastatic bone pain","volume":"70","author":"Purohit","year":"1994","journal-title":"Br J Cancer"},{"key":"R13-14-20211004","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"R14-14-20211004","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"R15-14-20211004","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1634\/theoncologist.11-7-841","article-title":"Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial","volume":"11","author":"Carteni","year":"2006","journal-title":"Oncologist"},{"key":"R16-14-20211004","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology. International Bone and Cancer Study Group","volume":"16","author":"Body","year":"1998","journal-title":"J Clin Oncol"},{"key":"R17-14-20211004","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","article-title":"Risks and benefits of bisphosphonates","volume":"98","author":"Coleman","year":"2008","journal-title":"Br J Cancer"},{"key":"R18-14-20211004","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1677\/erc.0.0110207","article-title":"Bisphosphonates in breast and prostate cancer","volume":"11","author":"Brown","year":"2004","journal-title":"Endocrine Related Cancer"},{"key":"R19-14-20211004","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer"},{"key":"R20-14-20211004","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long term efficacy of zoledronic acid for the prevention of complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R21-14-20211004","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial \u2013 the Zoledronic acid Lung Cancer and Other Solid Tumors Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"R22-14-20211004","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Mineral Res"},{"key":"R23-14-20211004","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdl093","article-title":"Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases","volume":"17","author":"Botteman","year":"2006","journal-title":"Ann Oncol"},{"key":"R24-14-20211004","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/01.ju.0000116777.94426.60","article-title":"Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer","volume":"171","author":"Reed","year":"2004","journal-title":"J Urol"},{"key":"R26-14-20211004","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1002\/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U","article-title":"Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma","volume":"88","author":"Yoneda","year":"2000","journal-title":"Cancer"},{"key":"R27-14-20211004","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/ijc.11330","article-title":"Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1\/luc mouse breast cancer","volume":"106","author":"Hiraga","year":"2003","journal-title":"Int J Cancer"},{"key":"R28-14-20211004","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/jnci\/djn240","article-title":"Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer","volume":"100","author":"Ottewell","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R30-14-20211004","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"R31-14-20211004","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","article-title":"Breast cancer cells interact with osteoblasts to support osteoclast formation","volume":"140","author":"Thomas","year":"1999","journal-title":"Endocrinology"},{"key":"R32-14-20211004","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO;2-Y","article-title":"Molecular mechanisms of osteolytic bone metastases","volume":"88","author":"Guise","year":"2000","journal-title":"Cancer"},{"key":"R36-14-20211004","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/17530050903473147","article-title":"Biomarkers of bone turnover in oncology: applications in diagnosis and treatment","volume":"4","author":"Brown","year":"2010","journal-title":"Expert Opin Med Diagnostics"},{"key":"R37-14-20211004","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/ctrv.2000.0212","article-title":"Bone markers in the management of metastatic bone disease","volume":"27","author":"Lipton","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"R38-14-20211004","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R39-14-20211004","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"R40-14-20211004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"R41-14-20211004","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"R43-14-20211004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/SPC.0b013e328133f5d8","article-title":"Update on radiation treatment for cancer pain","volume":"1","author":"Chow","year":"2007","journal-title":"Curr Opin Support Palliat Care"},{"key":"R44-14-20211004","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1007\/s00259-008-0841-y","article-title":"EANM procedure guideline for treatment of refractory metastatic bone pain","volume":"35","author":"Bodei","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R45-14-20211004","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.semnuclmed.2009.10.003","article-title":"Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain","volume":"40","author":"Paes","year":"2010","journal-title":"Semin Nucl Med"},{"key":"R46-14-20211004","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncol"},{"key":"R47-14-20211004","first-page":"3319","article-title":"Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer","volume":"27","author":"Tu","year":"2009","journal-title":"Clin Oncol"},{"key":"R48-14-20211004","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2008.18.9811","article-title":"Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration resistant prostate cancer","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"R49-14-20211004","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2174\/1871520610909030326","article-title":"The management of metastatic bone disease with the combination of bisphosphonates and radiotherapy: from theory to clinical practice","volume":"9","author":"Vassiliou","year":"2009","journal-title":"Anticancer Agents Med Chem"},{"key":"R50-14-20211004","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/jso.20949","article-title":"Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis","volume":"97","author":"Arrington","year":"2008","journal-title":"J Surg Oncol"},{"key":"R51-14-20211004","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/jpm.2009.9591","article-title":"Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined","volume":"12","author":"Lam","year":"2009","journal-title":"J Palliat Med"},{"key":"R52-14-20211004","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1007\/s00259-008-0759-4","article-title":"Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases","volume":"35","author":"Koutsikos","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201009000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T02:01:47Z","timestamp":1633312907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201009000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0b013e32833d3024","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}